Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19⁺ B cell tumors: a phase 1/2 trial.

ABSTRACT: There is a pressing need for allogeneic chimeric antigen receptor (CAR)-immune cell therapies that are safe, effective and affordable. We conducted a phase 1/2 trial of cord blood-derived natural killer (NK) cells expressing anti-CD19 chimeric antigen receptor and interleukin-15 (CAR19/IL-15) in 37 patients with CD19⁺ B cell malignancies. The primary objectives were safety and efficacy, defined as day 30 overall response (OR). Secondary objectives included day 100 response, progression-free survival, overall survival and CAR19/IL-15 NK cell persistence. No notable toxicities such as cytokine release syndrome, neurotoxicity or graft-versus-host disease were observed. The day 30 and day 100 OR rates were 48.6% for both. The 1-year overall survival and progression-free survival wer

SUBMITTER: Marin D 

PROVIDER: S-EPMC10957466 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature